dwb2023/gtopdb-target-family-interaction-detail huggingface dataset:
Target family: Phosphatidylcholine-specific phospholipase D (type: enzyme)
Target: PLD1

Ligand: compound 69 [PMID: 19136975] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.340000152587891 pIC50
Reference (Journal): Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Published in: Nat Chem Biol
Target family: Phosphatidylcholine-specific phospholipase D (type: enzyme)
Target: PLD2

Ligand: VU0364739 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.7 pIC50
Reference (Journal): Design, synthesis, and biological evaluation of halogenated N-(2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8-yl)ethyl)benzamides: discovery of an isoform-selective small molecule phospholipase D2 inhibitor.
Published in: J Med Chem

Ligand: PIP2 (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -
Reference (Journal): Cloning and initial characterization of a human phospholipase D2 (hPLD2). ADP-ribosylation factor regulates hPLD2.
Published in: J Biol Chem

Ligand: oleic acid (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -
Reference (Journal): Endogenous phospholipase D2 localizes to the plasma membrane of RBL-2H3 mast cells and can be distinguished from ADP ribosylation factor-stimulated phospholipase D1 activity by its specific sensitivity to oleic acid.
Published in: Biochem J

Ligand: FIPI (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.769999980926514 pIC50
Reference (Journal): Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Published in: Nat Chem Biol

Ligand: compound 69 [PMID: 19136975] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.03000020980835 pIC50
Reference (Journal): Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Published in: Nat Chem Biol

Ligand: ADP-ribosylation factor 1 (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -
Target family: Phosphatidylcholine-specific phospholipase D (type: enzyme)
Target: PLD1

Ligand: FIPI (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.020000457763672 pIC50
Reference (Journal): Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness.
Published in: Nat Chem Biol
Target family: Phosphatidylinositol-4-phosphate 3-kinase family (type: enzyme)
Target: phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta

Ligand: PI-103 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Published in: Bioorg Med Chem
Target family: Phosphatidylinositol-4-phosphate 3-kinase family (type: enzyme)
Target: phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha

Ligand: torin 2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.550000190734863 pIC50
Reference (Journal): Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Published in: J Med Chem
Target family: Phosphatidylinositol-4-phosphate 3-kinase family (type: enzyme)
Target: phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma

Ligand: SAR260301 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.420000076293945 pIC50
Reference (Journal): Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
Published in: J Med Chem
Target family: Phosphatidylinositol-4-phosphate 3-kinase family (type: enzyme)
Target: phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta

Ligand: torin 2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.610000133514404 pIC50
Reference (Journal): Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Published in: J Med Chem
Target family: Phosphatidylinositol kinases (type: enzyme)
Target: phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma

Ligand: AZD6482 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.960000038146973 pIC50
Reference (Journal): Human target validation of phosphoinositide 3-kinase (PI3K)β: effects on platelets and insulin sensitivity, using AZD6482 a novel PI3Kβ inhibitor.
Published in: J Thromb Haemost
Target family: Phosphatidylinositol kinases (type: enzyme)
Target: phosphatidylinositol 4-kinase alpha

Ligand: phenylarsine oxide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity:  -
Reference (Journal): Characterization of type II phosphatidylinositol 4-kinase isoforms reveals association of the enzymes with endosomal vesicular compartments.
Published in: J Biol Chem

Ligand: wortmannin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Functional expression and characterisation of a new human phosphatidylinositol 4-kinase PI4K230.
Published in: Biochim Biophys Acta

Ligand: wortmannin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase.
Published in: J Biol Chem
Target family: Phosphatidylinositol kinases (type: enzyme)
Target: phosphatidylinositol 4-kinase beta

Ligand: compound 22 [WO2019141694A1] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.399999618530273 pIC50
Reference (Patent): Pi4kiiibeta inhibitors

Ligand: PIK-93 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.71999979019165 pIC50
Reference (Journal): Maintenance of hormone-sensitive phosphoinositide pools in the plasma membrane requires phosphatidylinositol 4-kinase IIIalpha.
Published in: Mol Biol Cell

Ligand: PIK-93 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 7.71999979019165 pIC50
Reference (Journal): A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling.
Published in: Cell

Ligand: torin 2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.739999771118164 pIC50
Reference (Journal): Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Published in: J Med Chem

Ligand: wortmannin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Cloning and characterization of a wortmannin-sensitive human phosphatidylinositol 4-kinase.
Published in: J Biol Chem

Ligand: wortmannin (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Functional expression and characterisation of a new human phosphatidylinositol 4-kinase PI4K230.
Published in: Biochim Biophys Acta
Target family: Phosphatidylinositol kinases (type: enzyme)
Target: phosphatidylinositol 4-kinase type 2 alpha

Ligand: adenosine (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1989)
Median affinity:  pIC50
Reference (Journal): A homogeneous and nonisotopic assay for phosphatidylinositol 4-kinases.
Published in: Anal Biochem
Target family: Phosphatidylinositol kinases (type: enzyme)
Target: phosphatidylinositol 4-kinase type 2 beta

Ligand: adenosine (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1989)
Median affinity:  pIC50
Reference (Journal): A homogeneous and nonisotopic assay for phosphatidylinositol 4-kinases.
Published in: Anal Biochem
Target family: Phosphatidylinositol kinases (type: enzyme)
Target: phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 alpha

Ligand: torin 2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.550000190734863 pIC50
Reference (Journal): Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Published in: J Med Chem
Target family: Phosphatidylinositol kinases (type: enzyme)
Target: phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 beta

Ligand: PI-103 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8 pIC50
Reference (Journal): Synthesis and biological evaluation of sulfonylhydrazone-substituted imidazo[1,2-a]pyridines as novel PI3 kinase p110alpha inhibitors.
Published in: Bioorg Med Chem

Ligand: torin 2 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 7.610000133514404 pIC50
Reference (Journal): Discovery of 9-(6-aminopyridin-3-yl)-1-(3-(trifluoromethyl)phenyl)benzo[h][1,6]naphthyridin-2(1H)-one (Torin2) as a potent, selective, and orally available mammalian target of rapamycin (mTOR) inhibitor for treatment of cancer.
Published in: J Med Chem
Target family: Phosphatidylinositol kinases (type: enzyme)
Target: phosphatidylinositol-4-phosphate 3-kinase catalytic subunit type 2 gamma

Ligand: SAR260301 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 5.420000076293945 pIC50
Reference (Journal): Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
Published in: J Med Chem
Target family: Phosphatidylinositol phosphate kinases (type: enzyme)
Target: phosphatidylinositol-5-phosphate 4-kinase type 2 alpha

Ligand: BAY-091 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.890000343322754 pIC50
Reference (Journal): Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.
Published in: J Med Chem

Ligand: BAY-297 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.890000343322754 pIC50
Reference (Journal): Discovery and Characterization of the Potent and Highly Selective 1,7-Naphthyridine-Based Inhibitors BAY-091 and BAY-297 of the Kinase PIP4K2A.
Published in: J Med Chem
Target family: Phosphatidylinositol phosphate kinases (type: enzyme)
Target: phosphatidylinositol-4-phosphate 5-kinase type 1 alpha

Ligand: ISA-2011B (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity:  -
Reference (Journal): The role of PI3K/AKT-related PIP5K1α and the discovery of its selective inhibitor for treatment of advanced prostate cancer.
Published in: Proc Natl Acad Sci USA
Target family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (type: enzyme)
Target: phosphodiesterase 10A

Ligand: mardepodect (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: yes
Median affinity: 9.430000305175781 pIC50
Reference (Journal): Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia.
Published in: J Med Chem

Ligand: MK-8189 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.539999961853027 pKi
Reference (Journal): Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.
Published in: J Med Chem

Ligand: papaverine (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity: 7.679999828338623 pIC50
Reference (Journal): Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
Published in: Eur J Med Chem

Ligand: papaverine (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity: 7.769999980926514 pIC50
Reference (Journal): Synthesis and SAR study of new phenylimidazole-pyrazolo[1,5-c]quinazolines as potent phosphodiesterase 10A inhibitors.
Published in: Bioorg Med Chem

Ligand: PBF-999 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.239999771118164 pIC50
Reference (Patent): Pyrimidine derivatives as phosphodiesterase 10 inhibitors (PDE-10)

Ligand: PDE4 inhibitor 16 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 6.039999961853027 pIC50
Reference (Journal): Structure-Aided Identification and Optimization of Tetrahydro-isoquinolines as Novel PDE4 Inhibitors Leading to Discovery of an Effective Antipsoriasis Agent.
Published in: J Med Chem

Ligand: TC-E 5005 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.140000343322754 pIC50
Reference (Journal): Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.
Published in: J Med Chem
Target family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (type: enzyme)
Target: phosphodiesterase 11A

Ligand: BC11-38 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 6.5 pIC50
Reference (Journal): Identification of biologically active PDE11-selective inhibitors using a yeast-based high-throughput screen.
Published in: Chem Biol

Ligand: tadalafil (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: EMA (2002), FDA (2003)
Primary target: no
Median affinity: 6.519999980926514 pIC50
Reference (Journal): Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties.
Published in: J Med Chem
Target family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (type: enzyme)
Target: phosphodiesterase 1A

Ligand: calmodulin (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -

Ligand: crisaborole (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (2016), EMA (2020)
Primary target: no
Median affinity: 5.210000038146973 pIC50
Reference (Journal): Discovery and structure-activity study of a novel benzoxaborole anti-inflammatory agent (AN2728) for the potential topical treatment of psoriasis and atopic dermatitis.
Published in: Bioorg Med Chem Lett

Ligand: SCH51866 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.2 pIC50
Reference (Journal): Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
Published in: J Cardiovasc Pharmacol

Ligand: vinpocetine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Median affinity: 5.1 pIC50
Reference (Journal): Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases.
Published in: J Biol Chem
Target family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (type: enzyme)
Target: phosphodiesterase 1B

Ligand: calmodulin (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -

Ligand: lenrispodun (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 10.239999771118164 pIC50
Reference (Journal): Discovery of Potent and Selective Inhibitors of Phosphodiesterase 1 for the Treatment of Cognitive Impairment Associated with Neurodegenerative and Neuropsychiatric Diseases.
Published in: J Med Chem

Ligand: SCH51866 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.2 pIC50
Reference (Journal): Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
Published in: J Cardiovasc Pharmacol
Target family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (type: enzyme)
Target: phosphodiesterase 1C

Ligand: calmodulin (Peptide)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -

Ligand: compound 3m [PMID: 32603117] (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.539999961853027 pIC50
Reference (Journal): Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis.
Published in: J Med Chem

Ligand: SCH51866 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.2 pIC50
Reference (Journal): Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor.
Published in: J Cardiovasc Pharmacol

Ligand: vinpocetine (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Median affinity: 4.3 pIC50
Reference (Journal): Isolation and characterization of cDNAs corresponding to two human calcium, calmodulin-regulated, 3',5'-cyclic nucleotide phosphodiesterases.
Published in: J Biol Chem
Target family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (type: enzyme)
Target: phosphodiesterase 2A

Ligand: BAY607550 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  pIC50
Reference (Journal): Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance.
Published in: Neuropharmacology

Ligand: cyclic GMP (Metabolite)
Interaction type: Activator
Action: Activation
Ligand approved: no
Median affinity:  -

Ligand: EHNA (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 5.3 pIC50
Reference (Journal): Rapid regulation of PDE-2 and PDE-4 cyclic AMP phosphodiesterase activity following ligation of the T cell antigen receptor on thymocytes: analysis using the selective inhibitors erythro-9-(2-hydroxy-3-nonyl)-adenine (EHNA) and rolipram.
Published in: Cell Signal

Ligand: milrinone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1987)
Primary target: no
Median affinity: 6.519999980926514 pIC50
Reference (Journal): Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Published in: Biochem Pharmacol

Ligand: PF-05180999 (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Primary target: no
Median affinity: 8.800000190734863 pIC50
Reference (Journal): Identification of a Potent, Highly Selective, and Brain Penetrant Phosphodiesterase 2A Inhibitor Clinical Candidate.
Published in: J Med Chem
Target family: Phosphodiesterases, 3',5'-cyclic nucleotide (PDEs) (type: enzyme)
Target: phosphodiesterase 3B

Ligand: cilostamide (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity: 7.3 pIC50
Reference (Journal): Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Published in: Biochem Pharmacol

Ligand: cilostazol (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1999)
Primary target: yes
Median affinity: 6.420000076293945 pIC50
Reference (Journal): Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Published in: Biochem Pharmacol

Ligand: cyclic GMP (Metabolite)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: no
Median affinity:  -

Ligand: inamrinone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1984)
Primary target: yes
Median affinity: 4.510000228881836 pIC50
Reference (Journal): Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Published in: Biochem Pharmacol

Ligand: milrinone (Synthetic organic)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Approval source: FDA (1987)
Median affinity: 6 pIC50
Reference (Journal): Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity.
Published in: Biochem Pharmacol

Ligand: papaverine (Natural product)
Interaction type: Inhibitor
Action: Inhibition
Ligand approved: yes
Primary target: no
Median affinity: 5.989999771118164 pIC50
Reference (Journal): Synthesis and in vitro evaluation of new analogues as inhibitors for phosphodiesterase 10A.
Published in: Eur J Med Chem